These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. Zhou Y; Chen C; Zhang X; Fu S; Xue C; Ma Y; Fang W; Yang Y; Hou X; Huang Y; Zhao H; Hong S; Zhang L J Immunother Cancer; 2018 Dec; 6(1):155. PubMed ID: 30577837 [TBL] [Abstract][Full Text] [Related]
7. Atezolizumab and Its Many Uses. Saleh N; Copur MS Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469902 [No Abstract] [Full Text] [Related]
8. Immunotherapy for non-small cell lung cancer. Vafadar S JAAPA; 2019 Sep; 32(9):37-42. PubMed ID: 31460972 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant Therapy in Patients With Completely Resected Non-small-cell Lung Cancer: Current Status and Perspectives. Pirker R; Filipits M Clin Lung Cancer; 2019 Jan; 20(1):1-6. PubMed ID: 30309777 [TBL] [Abstract][Full Text] [Related]
11. Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC). Nørøxe DS; Wallerek S; Sørensen JB Anticancer Res; 2013 Aug; 33(8):3275-8. PubMed ID: 23898091 [TBL] [Abstract][Full Text] [Related]
12. AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany. Zahn MO; Linck D; Losem C; Gessner C; Metze H; Gaillard VE; Tessen HW BMC Cancer; 2019 May; 19(1):433. PubMed ID: 31077164 [TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: The 5-year outcomes of the KEYNOTE-024 trial. Li F; Dong X Thorac Cancer; 2021 Dec; 12(23):3085-3087. PubMed ID: 34643064 [No Abstract] [Full Text] [Related]
14. Bevacizumab in advanced lung cancer: state of the art. Assoun S; Brosseau S; Steinmetz C; Gounant V; Zalcman G Future Oncol; 2017 Dec; 13(28):2515-2535. PubMed ID: 28812378 [TBL] [Abstract][Full Text] [Related]
15. Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups. Yabuuchi H; Kawanami S; Iwama E; Okamoto I; Kamitani T; Sagiyama K; Yamasaki Y; Honda H Radiology; 2018 Feb; 286(2):685-695. PubMed ID: 29059037 [TBL] [Abstract][Full Text] [Related]
17. A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer. Gill HS; Ramalingam SS Cancer; 2019 Jul; 125(13):2148-2153. PubMed ID: 30825394 [No Abstract] [Full Text] [Related]
18. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. Puri S; Shafique M; Gray JE Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587 [TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for the first-line treatment of non-small cell lung cancer. Ninomiya K; Hotta K Expert Opin Biol Ther; 2018 Oct; 18(10):1015-1021. PubMed ID: 30207786 [TBL] [Abstract][Full Text] [Related]
20. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Zhang Y; Zhou H; Zhang L J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]